AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology
Friday, 24 April 2015
AstraZeneca and MedImmune, the Company's global biologics research and development arm, have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.
Roche reports strong sales growth in the first quarter of 2015
Thursday, 23 April 2015
The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in Pharmaceuticals, and immunodiagnostics products driving growth in Diagnostics.
Novo Nordisk today announced that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada.
Fastening protein-based medical treatments to nanoparticles isn't easy. With arduous chemistry, scientists can do it. But like a doomed marriage, the fragile binding that holds them together often separates. This problem, which has limited how doctors can use proteins to treat serious disease, may soon change.
GSK to establish global vaccines R&D centre in the US
Tuesday, 21 April 2015
GSK is further strengthening and expanding its vaccines presence in the US by establishing a new global centre for vaccines research and development (R&D) in Rockville, Maryland. The site will become one of three global vaccines R&D centres for GSK, complementing the company's existing global R&D centres in Rixensart, Belgium and in Siena, Italy, a site which GSK recently acquired from Novartis in March 2015.
New international survey of lung cancer oncologists highlights underutilization of personalized treatments
Monday, 20 April 2015
Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for EGFR mutations, a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype.
Researchers make key malarial drug-resistence finding
Friday, 17 April 2015
According to the World Health Organization's 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden.